1. Scrip
  2. >>Business

To Boost Or Not To Boost? Pfizer At Odds With US FDA

Pfizer Unphased By Apparent Pushback

 
• By Andrew McConaghie

US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.

US vaccination centre
Despite a rapid uptake from some US adults, so far only 54% have received at least one vaccine dose.

As many countries make plans for possible COVID-19 vaccine booster programs this fall, the US Food and Drug Administration and Centers for Disease Control have pushed back at the suggestion from Pfizer Inc. and BioNTech that the extra shots are necessary in the US – at least for now.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.